Editors: Donna E. Hansel, MD, PhD, division head of pathology and laboratory medicine, MD Anderson Cancer Center, Houston; James Solomon, MD, PhD, assistant professor, Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York; Erica Reinig, MD, assistant professor and medical director of molecular diagnostics, University of Wisconsin-Madison; Marcela Riveros Angel, MD, molecular genetic pathology fellow, Department of Pathology, Oregon Health and Science University, Portland; Maedeh Mohebnasab, MD, assistant professor of pathology, University of Pittsburgh; Alicia Dillard, MD, molecular pathologist, Sonic Healthcare USA, Rye Brook, NY; and Richard Wong, MD, PhD, assistant professor of pathology, University of California San Diego.
Use of IGH::FENDRR and KRAS mutations to define a novel B-ALL molecular subtype
November 2026—B-cell acute lymphoblastic leukemia (B-ALL) arises from a variety of genetic alterations impacting B-cell progenitors. Classification of B-ALL based on genetic type is associated with characteristic morphological, immunophenotypic, or clinical features with prognostic or therapeutic implications, or both. The International Consensus Classification of Myeloid Neoplasms and Acute Leukemias and the fifth edition of the World Health Organization Classification of Lymphoid Neoplasms define multiple molecular subtypes of B-ALL, as well as provisional entities. However, 10 to 15 percent of patients cannot be assigned to any of the subtypes, suggesting the existence of yet unidentified drivers. The authors conducted a study in which they identified a novel molecular subtype of B-ALL with recurrent distinct characteristics. They analyzed molecular data from 4,857 patients (3,572 adults and 1,285 children) from three B-ALL cohorts: GMALL (German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia), GRAALL (Group for Research on Adult Acute Lymphoblastic Leukemia), and St. Jude. The authors performed unsupervised analysis of the GMALL cohort of B-ALL patients (n = 767), identifying 77 patients without B-ALL subtype-defining driver aberrations. From these 77 patients, 799 differentially expressed genes that were not seen in the remaining ICC or WHO subclassified B-ALLs in the GMALL cohort were identified. The most strikingly upregulated genes were Forkhead protein 1 (FOXF1) and its adjacent FOXF1 enhancer-derived noncoding RNA (FENDRR), which the authors termed FOXF1/FENDRR. DNA methylation profiling confirmed the independence of a FOXF1/FENDRR cluster, despite some overlap with BCR::ABL1-positive/BCR::ABL1-like B-ALL. The authors identified 34 genes as specific to this FOXF1/FENDRR group based on feature selection and implemented them in the ALLCatchR 2802-gene signature for B-ALL subtype discrimination. They then trained a machine-learning classifier for these FOXF1/FENDRR cases, which specifically identified nine of nine patients with RNA sequencing (RNA-seq) in the training set. Testing on the independent GRAALL and St. Jude cohorts identified five of 1,154 and four of 1,988 additional patients, respectively. In 17 of the FOXF1/FENDRR signature-classified cases, the authors identified a previously undescribed IGH::FENDRR rearrangement. Genomic FENDRR breakpoints were intronic (n = 6 of 12) or downstream (n = 6 of 12) of FENDRR. FOXF1 was highly expressed in all cases, consistent with the assumption that the IGH enhancer is redirected to drive expression of FOXF1 and the remaining FENDRR exons. In addition, genomic profiling identified KRAS mutations in all patients with the FOXF1/FENDRR subtype, representing the only recurrent secondary aberration. This finding suggests that KRAS mutation may be a marker for identifying previously undescribed IGH::FENDRR rearrangement B-ALL cases. The most frequent variants were p.A146V/T/P (n = 17 of 20), whereas p.G12R, p.A18D, and p.E63K were detected in one case each. Outcome data for the FOXF1/FENDRR subtype patients showed one patient died during induction, two were stratified as high risk due to persistence of minimal residual disease (MRD), and eight were stratified as standard risk. Only three patients achieved complete MRD clearance after the first consolidation chemotherapy, indicating a poor chemotherapy response. Interestingly, the authors noted that FOXF1/FENDRR has recently been identified as a driver of a novel lineage-ambiguous high-risk T-cell acute lymphoblastic leukemia subtype in which FOXF1/FENDRR expression is driven from retargeting the BCL11B enhancer. The authors concluded that IGH::FENDRR and specific KRAS mutations define a novel B-ALL subtype in adults who have a distinct gene-expression or DNA-methylation signature and poor chemotherapy response.
Bendig S, Hartmann AM, Wessels W, et al. IGH::FENDRR and specific KRAS mutations define a novel B-ALL molecular subtype with poor chemotherapy response. Blood. 2026;148(8):1026–1032.
Correspondence: Dr. Monika Brüggemann at m.brueggemann@med2.uni-kiel.de
Ability of neonatal cytogenetic validation to demonstrate high accuracy of single-nucleotide polymorphism-based NIPT
Investigators first reported in 1997 that cell-free DNA (cfDNA) of fetal origin is present in maternal plasma. Since then, the use of cfDNA in prenatal testing has advanced to a clinical standard of care in many countries. Early studies showed that fetal trisomy 21 could be detected noninvasively by sequencing cfDNA in maternal plasma. This discovery became the basis for current noninvasive prenatal testing (NIPT) for common autosomal trisomies. In 2020, the American College of Obstetricians and Gynecologists and Society for Maternal-Fetal Medicine published a practice bulletin stating that all pregnant women, regardless of fetal chromosomal aneuploidy risk, should receive information about screening options, including NIPT, and make informed choices. A key point to emphasize is that NIPT is intended as a screening test and, as such, can generate false-positive results. NIPT results are not equivalent to nor intended to be used as diagnostic tests for specific fetal conditions. Misunderstanding about the role of NIPT in screening, among the lay public and even some perinatal medical providers, has led to controversy regarding its clinical use in pregnancy decision-making. NIPT is highly accurate compared to maternal serum marker tests and ultrasound examinations, but its accuracy generally has been evaluated based on pregnancy outcomes rather than cytogenetic confirmation using samples from newborns. The authors conducted a study in which they evaluated the performance of single-nucleotide polymorphism (SNP)-based NIPT in a single-center Japanese cohort over a 10-year period. They performed cytogenetic confirmation not only in positive cases but also across a large cohort of negative cases using postnatal buccal mucosal FISH analysis. The study cohort included 4,466 women who underwent NIPT between October 2013 and June 2022. Overall, 4,366 of the 4,466 patient tests were negative (97.0 percent), 73 were positive (1.6 percent), and four yielded “no call” results even after repeat testing (0.1 percent). Of the 73 patients with positive NIPT results, nine miscarried before karyotype confirmation and 64 underwent cytogenetic confirmation. Positive predictive value (PPV) was calculated for cases with definitive cytogenetic confirmation. Seven false-positive cases were identified, yielding an overall PPV of 89.1 percent (57 of 64), with PPV for trisomies 13, 18, and 21 being 57.1 percent (four of seven), 90.0 percent (18 of 20), and 94.6 percent (35 of 37), respectively. Postnatal cytogenetic confirmation using neonatal buccal mucosal FISH analysis was available for 3,579 of the 4,366 NIPT-negative cases (81.8 percent). Based on postnatal cytogenetic confirmation using neonatal buccal mucosal FISH, two false-negative cases were identified among the 3,579 NIPT-negative pregnancies (0.06 percent), resulting in a negative predictive value (NPV) of 99.9 percent for trisomies 13, 18, and 21. The authors found that their SNP-based NIPT performed well as a screening test (89.1 percent PPV, 99.9 percent NPV). Although the mechanisms underlying discordant NIPT results are not fully understood, previous reviews have suggested several potential causes, including placental mosaicism, maternal copy number variation, vanishing twin, maternal malignancy, and true fetal mosaicism.
Uchida S, Mizuguchi Y, Sato S, et al. Neonatal cytogenetic validation demonstrates high accuracy of single-nucleotide polymorphism-based non-invasive prenatal testing: a 4466-case single-center study. J Hum Genet. 2026;71(9):579–585.
Correspondence: Dr. Yuki Mizuguchi at ymizuguchi_2@yahoo.co.jp